Table 2.
Summary of lncRNAs as cardiovascular biomarkers
| LncRNA | Disease | Application | Study type | Study size | Follow-up |
|---|---|---|---|---|---|
| ANRIL (NR_003529 & DQ485454) | CAD[30] | Risk factor | Cross-sectional | 1134 atherosclerosis patients | None |
| ANRIL (all transcripts) | MI[95] | LV dysfunction predictors | Cohort | 414 MI; 86 healthy | 4 month |
| LIPCAR | MI & HF[94] | Cardiac death and cardiac remodelling predictors | Cohort | 246 MI | 12 months |
| Cohort | 344 HF | 3 years | |||
| Case-control | 99 died and 99 alive from HF | 3 years | |||
| KCNQ1OT | MI[95] | LV dysfunction predictors | Cohort | 414 MI; 86 healthy | 4 month |
|
HIF1αAS2 |
MI[95] | None | Cohort | 414 MI; 86 healthy | 4 month |
|
MALAT1 |
MI[95] | None | Cohort | 414 MI; 86 healthy | 4 month |
|
MIAT |
MI[95] | None | Cohort | 414 MI; 86 healthy | 4 month |
| MIAT | MI[68] | Risk factor | Case-control | 3464 MI; 3819 healthy | None |